top of page
Rethinking Medications Book Cover.jpg

Rethinking Medications: From Academic Detailing to Broken Drug Regulation

  • Jan 25
  • 1 min read

Updated: Jun 29



Harvard professor Jerry Avorn and I discuss drug regulation, FDA approval standards, surrogate endpoints, pharmaceutical pricing, public research funding, medical misinformation, and what all of this means for patients, innovation, and health policy.

Recent Posts

See All
Healing Our De-Commissioned FDA

From HealthAffairs. By Aaron S. Kesselheim and Jerry Avorn. At a time of rapidly developing new medications and growing public health challenges, there is now no official leadership in place at the Fo

 
 
bottom of page